57.63

1.25% -0.73

After Hours: 57.25 -0.38 -0.66%

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $57.63, with a volume of 3.24M. It is down -1.25% in the last 24 hours and down -7.53% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$58.36

Open:

$58.36

24h Volume:

3.24M

Relative Volume:

1.12

Market Cap:

$25.66B

Revenue:

$2.44B

Net Income/Loss:

$1.36B

P/E Ratio:

30.18

EPS:

1.9093

Net Cash Flow:

$574.14M

1W Performance:

-1.13%

1M Performance:

-7.53%

6M Performance:

+18.85%

1Y Performance:

+58.67%

1-Day Range:

$57.22

$58.40

1-Week Range:

$57.22

$58.77

52-Week Range:

$35.23

$64.38

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1068)

Industry

Biotechnology (594)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

100

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	57.63	25.92B	2.44B	1.36B	574.14M	1.9093
VRTX Vertex Pharmaceuticals Inc	506.74	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	734.81	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	188.94	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	936.00	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	205.89	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Upgrade	UBS	Neutral → Buy
Sep-30-25	Initiated	Goldman	Buy
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

01:02 AM

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - theglobeandmail.com

01:02 AM

12:30 PM

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool

12:30 PM

02:44 AM

Form 4 Royalty Pharma Plc For: 1 October - Investing.com India

02:44 AM

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria

Sep 30, 2026

Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com

Sep 30, 2026

Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 4,126 Shares of Stock - MarketBeat

Sep 30, 2026

A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan

Sep 30, 2026

4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan

Sep 30, 2026

Sep 29, 2026

If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga

Sep 29, 2026

Operating cash flow per share of Royalty Pharma Plc Class A – HAN:RPD - TradingView

Sep 29, 2026

RPD Forecast — Price Target — Prediction for 2027 - TradingView

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026

RPHC5824522 Bond Profile: Coupon and Redemption - TradingView

Sep 29, 2026

Sep 28, 2026

Royalty Pharma officer proposes $239K share sale | RPRX SEC FilingForm 144 - Stock Titan

Sep 28, 2026

Sep 27, 2026

Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Australia

Sep 27, 2026

Sep 26, 2026

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Eastern Progress

Sep 26, 2026

Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Buy at Wall Street Zen - MarketBeat

Sep 26, 2026

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com

Sep 25, 2026